Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients

CNS Drugs

Volumn 29, Issue 6, 2015, Pages 503-510

  Johnson, Barbara H ^a   Bonafede, Machaon M ^a   Watson, Crystal ^b  

^a IBM WATSON HEALTH   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; BETA INTERFERON; IMMUNOLOGIC FACTOR;

ADULT; AGED; ARTICLE; COMORBIDITY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PLATFORM THERAPY; PRIORITY JOURNAL; PROPENSITY SCORE; RECURRENCE RISK; ADOLESCENT; COMPARATIVE STUDY; DISABILITY; DRUG DATABASE; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DATABASES, PHARMACEUTICAL; DISABILITY EVALUATION; FEMALE; GLATIRAMER ACETATE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NATALIZUMAB; PROPENSITY SCORE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84938210405     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-015-0251-1     Document Type: Article

References (17)

1. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366:339-47.
2. Kantarci OH, Pirko I, Rodriguez M. Novel immunomodulatory approaches for the management of multiple sclerosis. Clin Pharmacol Ther. 2014;95:32-44.
3. Elovaara I. Early treatment in multiple sclerosis. J Neurol Sci. 2011;311(Suppl 1):S24-8.
4. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
5. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;71:766-73.
6. Nicholas JA, Racke MK, Imitola J, Boster AL. First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks. Ther Adv Chronic Dis. 2014;5:62-8.
7. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169-78.
8. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254-60.
9. Bonafede MM, Johnson BH, Watson C. Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US. Clinicoecon Outcomes Res CEOR. 2013;6:11-20.
10. Prosperini L, Gianni C, Leonardi L, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler. 2012;18:64-71.
11. Lanzillo R, Bonavita S, Quarantelli M, et al. Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. Neurol Sci. 2013;34:521-8.
12. Spelman T, Pellegrini F, Zhang A, et al. Comparison of patients treated with natalizumab and interferon beta/glatiramer using propensity-matched multiple sclerosis registry data. The 65th Annual Meeting of the American Academy of Neurology. San Diego, CA; 2013.
13. Clinical Coulthard-Morris L, Measures Rehabilitation. In: Burks JS, Johnson KP, editors. Multiple sclerosis diagnosis, medical management, and rehabilitation. New York: Demos Medical Publishing Inc; 2000. p. 221-90.
14. Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Political Anal. 2007;15:199-236.
15. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8:469-76.
16. Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13:618-25.
17. Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85:1190-7.